Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ImmunoGen, Inc. - Common Stock (NQ:IMGN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ImmunoGen, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2022 Operating Results
From ImmunoGen Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Why Are ImmunoGen Shares Trading Lower Today
ImmunoGen Inc (NASDAQ: IMGN)  
Via Benzinga
ImmunoGen Announces Webcast of Panel Discussion at Upcoming Canaccord Genuity Horizons in Oncology Virtual Conference
From ImmunoGen, Inc.
Via Business Wire
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
ImmunoGen Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer
From ImmunoGen, Inc.
Via Business Wire
75 Biggest Movers From Yesterday
Gainers NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) shares jumped 299.4% to close at $6.23 on Monday as the company received clearance from the FDA to initiate a pharmacokinetic... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 39 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap to set a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2022
Upgrades According to B. Riley Securities, the prior rating for BRT Apartments Corp (NYSE:BRT) was changed from Neutral to Buy. BRT Apartments earned $0.41 in the fourth quarter,... 
Via Benzinga
46 Stocks Moving In Monday's Mid-Day Session
Gainers NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) climbed 369% to $7.32 as the company received clearance from the FDA to initiate a pharmacokinetic study of PrimeC in... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Corbus Pharmaceuticals (NASDAQ:CRBP) shares increased by 20.3% to $0.4 during Monday's pre-market session. The market value of their outstanding shares is at $49.7 million. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, investor! We're getting right into the thick of it with a look at the biggest pre-market stock movers for Monday! 
Via InvestorPlace
28 Stocks Moving in Monday's Pre-Market Session
Gainers BitNile Holdings, Inc. (NYSE: NILE) rose 61.1% to $0.90 in pre-market trading. BitNile's TurnOnGreen resumed expansion of its electric vehicle charging network and e-... 
Via Benzinga
ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at SGO Annual Meeting
From ImmunoGen, Inc.
Via Business Wire
The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Lilly's Co-developed Diabetes Drug Jardiance Gets Label Expansion To... 
Via Benzinga
Immunogen: Q4 Earnings Insights
Immunogen (NASDAQ:IMGN) reported its Q4 earnings results on Friday, February 25, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
ImmunoGen Reports Recent Progress and 2021 Financial Results
From ImmunoGen Inc.
Via Business Wire
Earnings Scheduled For February 25, 2022
Companies Reporting Before The Bell • ACM Research (NASDAQ:ACMR) is estimated to report quarterly earnings at $0.64 per share on revenue of $89.53 million. •... 
Via Benzinga
Earnings Outlook For Immunogen
Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2022-02-25. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
ImmunoGen Announces Webcast of Panel Discussion at Upcoming Cowen 42nd Annual Health Care Conference
From ImmunoGen, Inc.
Via Business Wire
Lilly Unites With ImmunoGen In ADC Deal Worth Up To $1.7B
ImmunoGen Inc (NASDAQ: IMGN) has struck a multi-target license deal with Eli Lilly And Co (NYSE: LLY) to grant exclusive rights to research, develop, and... 
Via Benzinga
ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion
From ImmunoGen Inc.
Via Business Wire
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
ImmunoGen Announces Conference Call to Discuss Its 2021 Operating Results
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming SVB Leerink 11th Annual Global Healthcare Conference
From ImmunoGen, Inc.
Via Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen Inc.
Via Business Wire
ImmunoGen Appoints Mimi Huizinga, MD, as Senior Vice President and Head of Medical Affairs
From ImmunoGen Inc.
Via Business Wire
Sutro Biopharma Collapses; Why One Analyst Remains Bullish On Its Chances In Cancer
Sutro Biopharma could still find a place for itself in ovarian cancer treatment. 
Via Investor's Business Daily
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.